{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:40:46Z","timestamp":1648820446761},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1992,1,1]],"date-time":"1992-01-01T00:00:00Z","timestamp":694224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/bf00686253","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T16:26:22Z","timestamp":1101745582000},"page":"201-206","source":"Crossref","is-referenced-by-count":0,"title":["A clinical and pharamcological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue"],"prefix":"10.1007","volume":"29","author":[{"given":"Mark","family":"McKeage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Clear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/bjc.1986.13","volume":"53","author":"CJ Brindley","year":"1985","unstructured":"Brindley CJ, Antoiw P, Newlands ES (1985) Plasma and tumour disposition of mitozolomide in mice. Br J Cancer 53: 91","journal-title":"Br J Cancer"},{"key":"CR2","first-page":"257","volume-title":"Cancer: principles and practice of oncology","author":"VT Vita De","year":"1985","unstructured":"De Vita VT (1985) Principles of chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. 2nd edn. J. B. Lippincott, Philadelphia, p 257","edition":"2nd edn."},{"key":"CR3","first-page":"1778","volume":"45","author":"O Fodstad","year":"1985","unstructured":"Fodstad O, Aamdal S, Pihl A, Boyd M (1985) Activity of mitozolomide (NSC 35 3451), a new imidazoterazine, against xenografts from human melanomas, sarcomas, lung and colon carcinomas. Cancer Res 45: 1778","journal-title":"Cancer Res"},{"key":"CR4","first-page":"111","volume-title":"Bone marrow and organ transplantation","author":"RP Gale","year":"1984","unstructured":"Gale RP (1984) Autologous bone marrow transplantation in patients with cancer. In: Slavin S (eds) Bone marrow and organ transplantation. Elsevier, Amsterdam, p 111"},{"key":"CR5","first-page":"1772","volume":"44","author":"NW Gibson","year":"1984","unstructured":"Gibson NW, Hickman JA, Erickson LC (1984) DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res 44: 1772","journal-title":"Cancer Res"},{"key":"CR6","first-page":"1767","volume":"44","author":"NW Gibson","year":"1984","unstructured":"Gibson NW, Erickson LC, Hickman JA (1984) Effects of the antitumour agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res 44: 1767","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York","edition":"2nd edn."},{"key":"CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.1985.145","volume":"52","author":"C Goddard","year":"1985","unstructured":"Goddard C, Slack JA, Stevens MFG (1985) Antitumour imidazotetrazines: IX. The pharmacokinetics of mitozolomide in mice. Br J Cancer 52: 37","journal-title":"Br J Cancer"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/bjc.1987.85","volume":"55","author":"S Gundersen","year":"1987","unstructured":"Gundersen S, Aamdal S, Fodstad O (1987) Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br J Cancer 55: 433","journal-title":"Br J Cancer"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/bjc.1988.21","volume":"57","author":"M Harding","year":"1988","unstructured":"Harding M, Northcott D, Smyth J, Stuart J, Green JA, Newlands E (1988) Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 57: 113","journal-title":"Br J Cancer"},{"key":"CR11","first-page":"3008","volume":"45","author":"JA Hickman","year":"1985","unstructured":"Hickman JA, Stevens MFG, Gibson NW, Langdon SP, Fizames C, Lavelle F, Atassi G, Lunt E, Tilson RM (1985) Experimental antitumour activity against murine tumour model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad spectrum agent. Cancer Res 45: 3008","journal-title":"Cancer Res"},{"key":"CR12","first-page":"797","volume":"70","author":"RA Joss","year":"1986","unstructured":"Joss RA, Hyssel HJ, Biscoff AK, Goldhirsch A, Brunner KW (1986) Abbreviated phase I clinical trial of i. v. mitozolomide. Cancer Treat Rep 70: 797","journal-title":"Cancer Treat Rep"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00686236","volume":"25","author":"DJ Kerr","year":"1990","unstructured":"Kerr DJ, Slack JA, Secrett P, Stevens MFG, Blackledge GRP, Bradley C, Kaye SB (1990) Relationship between the pharmacokinetics and the toxicity of mitozolomide. Cancer Chemother Pharmacol 25: 352","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR14","first-page":"9","volume-title":"Autologous bone marrow transplantation and solid tumours","author":"JL Millar","year":"1984","unstructured":"Millar JL, Smith IE (1984) The viability of marrow stored at 4\ufffdC. In: McVie JG, Dalesio O, Smith IE (eds) Autologous bone marrow transplantation and solid tumours. Raven Press, New York, p 9"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"41","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 41: 207","journal-title":"Cancer"},{"key":"CR16","first-page":"801","volume":"69","author":"ES Newlands","year":"1985","unstructured":"Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MFG (1985) Phase I clinical trial of mitozolomide. Cancer Treat Rep 69: 801","journal-title":"Cancer Treat Rep"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00253003","volume":"6","author":"G Powis","year":"1981","unstructured":"Powis G, Ames MM, Kovach JS (1981) Dose-dependent pharmacokinetics and cancer chemotherapy. Cancer Chemother Pharmacol 6: 1","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR18","first-page":"5","volume-title":"Autologous bone marrow transplantation and solid tumours","author":"R Raymakers","year":"1984","unstructured":"Raymakers R, Witte T de, Ouweland F van der, Geerdink P, Wessels H, Haanen C (1984) Enrichment and cryopreservation of autologous marrow. In: McVie JG, Dalesio O, Smith IE (eds) Autologous bone marrow transplantation and solid tumours. Raven Press, New York, p 5"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0378-4347(85)80027-X","volume":"337","author":"JA Slack","year":"1985","unstructured":"Slack JA, Goddard C (1985) Antitumour imidazotetrazines: VII. Quantitative analysis of mitozolomide in biological fluids by highperformance liquid chromatography. J Chromatogr 337: 178","journal-title":"J Chromatogr"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0277-5379(89)90216-2","volume":"25","author":"JF Smyth","year":"1989","unstructured":"Smyth JF, Gunderson S, Renard J, Pinedo HM (1989) Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. Eur J Cancer Clin Oncol 25: 755","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm00368a016","volume":"27","author":"MFG Stevens","year":"1984","unstructured":"Stevens MFG, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG (1984) Antitumour imidazotetrazines: 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent. J Med Chem 27: 196","journal-title":"J Med Chem"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4612-4974-0_40","volume-title":"Manual of pharmacologic calculations with computer programs","author":"RJ Tallarida","year":"1987","unstructured":"Tallarida RJ, Murray RB (1987) Manual of pharmacologic calculations with computer programs, 2nd edn. Springer, New York, p 131","edition":"2nd edn."},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0277-5379(89)90422-7","volume":"25","author":"AT Oosterom Van","year":"1990","unstructured":"Van Oosterom AT, Stoter G, Bono AV, Splinter TAW, Fossa SD, Verbaeys AJ, De Mulder PHM, De Pauw M, Sylvester R (1990) Mitozolomide in advanced renal cancer. Eur J Cancer Clin Oncol 25: 1249","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR24","first-page":"438","volume":"52","author":"P Workman","year":"1984","unstructured":"Workman P, Lee FYF, Donaldson J (1984) Pharmacokinetic factors affecting comparative tumour response to CCNU and mitozolomide. Br J Cancer 52: 438","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686253\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T01:28:11Z","timestamp":1625016491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992]]}},"alternative-id":["BF00686253"],"URL":"https:\/\/doi.org\/10.1007\/bf00686253","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992]]}}}